--- title: New FDA Guidance on Clinical Trial Diversity description: U.S. FDA took an important step to increase racial and ethnic diversity in clinical trials by releasing new draft guidance to the industry. image: https://blog.acclinate.com/hubfs/11.png --- [![Acclinate Logo](https://blog.acclinate.com/hs-fs/hubfs/Acclinate-logo.png?width=2000&height=497&name=Acclinate-logo.png "Acclinate Logo")](https://www.acclinate.com/) - Products - [NOWINCLUDED](https://www.acclinate.com/products/nowincluded-the-community) - [eDICT](https://www.acclinate.com/products/e-dict) - Solutions - [Pharmaceutical Companies](https://www.acclinate.com/solutions/for-pharmaceutical-companies) - [Contract Research Organizations](https://www.acclinate.com/solutions/for-cros) - [Partners](https://www.acclinate.com/solutions/community-partners) - Company - [About Us](https://www.acclinate.com/about) - [Careers](https://www.acclinate.com/careers) - [News](https://news.acclinate.com) - Resources - [Resource Library](https://www.acclinate.com/resources) - [Blog](https://blog.acclinate.com) - [Press Kit](https://www.acclinate.com/press-kit) - [Events](https://www.acclinate.com/events) - [Glossary](https://www.acclinate.com/glossary) - [FAQ](https://www.acclinate.com/faq) - [Talk to Our Team](https://info.acclinate.com/get-in-touch) [![Talk to Our Team](https://no-cache.hubspot.com/cta/default/19943632/2e1c34dc-aaa1-43b8-b5f4-469b0db4e302.png)](https://cta-redirect.hubspot.com/cta/redirect/19943632/2e1c34dc-aaa1-43b8-b5f4-469b0db4e302) [![Acclinate Logo](https://blog.acclinate.com/hs-fs/hubfs/Acclinate_Logo.png?width=500&height=149&name=Acclinate_Logo.png "Acclinate Logo")](https://www.acclinate.com/) - Products - [**NOWINCLUDED**Acclinate’s B2C community platform ](https://www.acclinate.com/products/nowincluded-the-community) - [**e-DICT**Acclinate’s patented AI-powered technology ](https://www.acclinate.com/products/e-dict) - Solutions - [**Pharmaceutical Companies**Community-driven recruitment and real-world insights to support diverse, compliant clinical trials. ](https://www.acclinate.com/solutions/for-pharmaceutical-companies) - [**Contract Research Organization (CRO)**Scalable patient engagement and recruitment solutions that reduce risk and improve enrollment timelines. ](https://www.acclinate.com/solutions/for-cros) - [**Partners**Trusted partnerships that connect research opportunities with the communities they aim to serve. ](https://www.acclinate.com/solutions/community-partners) - Company - [**About us**We help clinical research teams reach diverse communities, build trust, and improve trial participation. ](https://www.acclinate.com/about) - [**Careers**Join a mission-driven team advancing inclusive clinical research and community-powered health innovation. ](https://www.acclinate.com/careers) - Resources - [**Resources Hub** ](https://www.acclinate.com/resources) - [**Glossary** ](https://www.acclinate.com/glossary) - [**Press Kit** ](https://www.acclinate.com/press-kit) - [**Events** ](https://www.acclinate.com/events) - [**Blog** ](https://blog.acclinate.com/) - [**News** ](https://news.acclinate.com/) - [![](https://cdn.prod.website-files.com/695fbca039298e2117988a78/69e7b588548c7ad7bd8ab0bc_9dd915489696393dc63d7785ee2e52c7_Question%20mark%20image.png) **FAQs** ](https://www.acclinate.com/faq) - [ Contact Us ](https://www.acclinate.com/contact-us) Stay up to date Get news directly in your inbox Topic All - [Affective Trust ](https://blog.acclinate.com/tag/affective-trust) - [Announcement ](https://blog.acclinate.com/tag/announcement) - [Clinical Research Software ](https://blog.acclinate.com/tag/clinical-research-software) - [Clinical Trial Recruitment Strategies ](https://blog.acclinate.com/tag/clinical-trial-recruitment-strategies) - [Community ](https://blog.acclinate.com/tag/community) - [Diversity in Clinical Trials ](https://blog.acclinate.com/tag/diversity-in-clinical-trials) - [e-DICT™ ](https://blog.acclinate.com/tag/e-dict) - [FDA Diversity Plan ](https://blog.acclinate.com/tag/fda-diversity-plan) - [FDA Guidance: Diversity in Clinical Trials ](https://blog.acclinate.com/tag/fda-guidance-diversity-in-clinical-trials) - [Health Equity ](https://blog.acclinate.com/tag/health-equity) - [Partnerships ](https://blog.acclinate.com/tag/partnerships) - [Representation in Healthcare ](https://blog.acclinate.com/tag/representation-in-healthcare) [FDA Guidance: Diversity in Clinical Trials](https://blog.acclinate.com/topic/fda-guidance-diversity-in-clinical-trials) # Pharma's Response to New FDA Guidance on Clinical Trial Diversity U.S. FDA took an important step to increase racial and ethnic diversity in clinical trials by releasing new draft guidance to the industry. ![Assessing Pharma's Response to New FDA Guidance on Clinical Trial Diversity](https://blog.acclinate.com/hubfs/11.png) Clinical Trial Diversity: What Does It Really Mean? Clinical trials are critical for evaluating the safety and effectiveness of medical devices and pharmaceutical products. The results of trials guide t... Read More ![ Acclinate](https://blog.acclinate.com/hubfs/69b96486c4b036c19f462c19_acclinate-logo.png) [Acclinate](https://blog.acclinate.com/author/acclinate) Acclinate turns trust and data into better representation. Share this Post: [**](https://www.facebook.com/sharer/sharer.php?u=https://blog.acclinate.com/a-change-gone-come-assessing-pharmas-response-to-new-fda-guidance-on-clinical-trial-diversity) [**](https://twitter.com/home?status=https://blog.acclinate.com/a-change-gone-come-assessing-pharmas-response-to-new-fda-guidance-on-clinical-trial-diversity) [** ](https://www.linkedin.com/shareArticle?mini=true&url=https://blog.acclinate.com/a-change-gone-come-assessing-pharmas-response-to-new-fda-guidance-on-clinical-trial-diversity&title=New%20FDA%20Guidance%20on%20Clinical%20Trial%20Diversity) Stay up to date Get news directly in your inbox Today, the U.S. Food and Drug Administration took an important step to increase racial and ethnic diversity in clinical trials by releasing new draft guidance to the industry. The guidance comes as a group of legislators seeks to compel pharmaceutical companies to do more to encourage diverse clinical enrollment for the drugs they sponsor. Current legislative bills to tackle clinical trial diversity include: - Cures 2.0 (**H.R. 6000**) - The DIVERSE Trials Act (**H.R. 5030**) - The Equity in Neuroscience and Alzheimer’s Clinical Trials Act of 2021 (**H.R. 3085**) The [**pharmaceutical industry trade group has exerted considerable effort**](https://news.bloomberglaw.com/pharma-and-life-sciences/clinical-trial-diversity-mandates-draw-drug-industry-resistance) to get legislators to back off specific mandates aimed at improving the diversity of clinical trial participants. The new FDA guidance stops short of mandates but requires pharmaceutical companies to develop specific plans to ensure the representative enrollment of certain populations in their pivotal studies. [![Download Now – Diversifying Clinical Trials: 8 Best Practices](https://no-cache.hubspot.com/cta/default/19943632/interactive-163343460273.png) ](https://blog.acclinate.com/hs/cta/wi/redirect?encryptedPayload=AVxigLK4quL0AEEM3GbqddLFwS0NtbpQ8Nk6hjm8GGraM591n4HiS%2FFRxG1wurcPAlpU6VFM1HqHENYaBA9Vj%2FZFKfM%2FNJAchigMwyEGd0BjmHv09Xjs03uE%2FwAgPygFWQuIzymVh5MpvBhFMNCfoBWcjcKgKklO2sAIEoUarYpIvhfTn5ZJ2U6mRXXw1CLKFU6OGkqj2VnlvZrGY2eOg98u4%2Bhhb%2BakcWK9utwYwQ%3D%3D&webInteractiveContentId=163343460273&portalId=19943632) Specifically, the guidance informs pharmaceutical sponsors of clinical trials to: - *Describe in detail the operational measures that will be implemented to enroll and retain underrepresented racial and ethnic participants in the planned trial(s) or studies, and the planned use of data to characterize safety, efficacy, and optimal dosage in these participants, when applicable*. - *Describe specific trial enrollment and retention strategies, including but not limited to site location and access, sustained community engagement, and reducing burdens due to trial/study design/conduct.* - *Describe metrics to ensure that diverse participant enrollment goals are achieved and specify actions to be implemented during the conduct of the trial(s) or studies if planned enrollment goals are not met.*‍ Over the past two years, Acclinate has worked or consulted with numerous pharmaceutical companies in their efforts to achieve adequate racial and ethnic diversity in their clinical trials. Specifically, we’ve had in-depth discussions with twenty-five drug sponsors, covering the spectrum from emerging biopharma to international pharmaceutical companies with household names. What emerged from those discussions was a taxonomy for categorizing each company’s posture to the imminent industry and regulatory changes based on their *strategic orientation* and *proactiveness*. Strategic orientation can be defined as identifying a current state and intended future state, complete with the main goals and objectives, and then building the corresponding vision, mission, values, and procedural plan to achieve them. Proactiveness can be defined as anticipating challenges, seeking new solutions, and taking intervening action. These are often self-initiated behaviors intended to solve a problem before they occur or become worse. A 2x2 matrix with four distinct quadrants emerged when we combined the level of strategic orientation and the level of proactiveness exhibited by the twenty-five pharmaceutical companies we've worked or consulted with. Figure: 2x2 Matrix of 25 Pharma Companies ![2x2 Matrix of Pharma Client Postures](https://blog.acclinate.com/hubfs/Imported_Blog_Media/64ee7ebf711c42cfdd7beacc_1649861469418.png) ### **Business as Usual** Pharmaceutical companies in this quadrant have **low strategic orientation and** **low proactiveness**. One might refer to this as the proverbial “head in the sand” approach of refusing to acknowledge an imminent external change, even when not responding to the change may be existential. The good news is that only 10% of the pharmaceutical companies that we’ve interacted with reside in this quadrant. [**Recent examples of the FDA not granting drug approval**](https://www.fiercepharma.com/pharma/fda-sets-example-through-eli-lilly-innovent-s-pd-1-rocking-boat-for-future-contenders) for trials without adequate racial and ethnic representation is a wake-up call for pharmaceutical companies to move from this posture quickly. ### **Unrealized Intentions** Pharmaceutical companies in this quadrant have **high strategic** **orientation** **but low proactiveness**. Nearly half the pharma companies fall within this quadrant. These companies suffer from “analysis paralysis” and often have meetings to plan for their meetings and working groups within subcommittees of the larger group. You might hear a DEI lead from a pharmaceutical company in this quadrant say, “This year we will develop the plan, next year we will get the plan approved, and then in year three, establish benchmarks against the plan.” Companies in this quadrant may be relatively safe for the short term based on the new FDA guidance. However, they will significantly erode their competitive advantage and lead in the marketplace related to clinical trial diversity. ### **Trial & Error** Pharmaceutical companies in this quadrant have **low strategic orientation** **but high proactiveness**. Approximately 30% of pharmaceutical companies fall within this quadrant. They effectively recognize there is no silver bullet solution to clinical trial diversity, but they overcompensate by using the equivalent of a low-powered shotgun. With just a little planning, they are off to the races on several piecemeal “initiatives” – new connections with patient advocacy groups, supporting efforts to diversify the industry’s principal investigators, interviewing decentralized clinical trial providers, and spinning up new sites in majority-minority metro areas. These pharma companies will see some improvement in their clinical trial diversity, especially compared to companies residing in the Unrealized Intentions quadrant. The incremental gains may come with significant investment but a nominal ROI. ### **Leveraging Change** Pharmaceutical companies in this quadrant have **high strategic orientation and high proactiveness**. Approximately 10% of the pharmaceutical companies we’ve interacted with fall within this quadrant. These companies have adopted a type of strategic agility that allows them to accurately anticipate future consequences and trends, recognize strategic opportunities created by the change, and implement innovative strategies. They often utilize pilot programs to run planning, implementing, learning, and iterating cycles. Pharma companies in this quadrant objectively [**assess their clinical trial diversity against a standardized metric**](https://www.linkedin.com/pulse/what-gets-measured-done-time-standardized-industry-smith-ph-d-/?trackingId=49hB928yUqO7CMh%2FWST02A%3D%3D) and produce an upward trend line from the process. They also see how the modifications meant to increase diversity can positively drive key performance indicators like patient accrual and retention. Pharmaceutical companies in this quadrant will utilize the recent FDA guidance to establish themselves as market leaders further. ### ** "A Change Gonna Come"** The pharmaceutical industry has been characterized as slow to change. However, history tells us that the industry can quickly adapt when faced with regulator pressures and mandates designed to provide better accountability and outcomes (e.g., IRB and HIPAA). The FDA first issued its [**draft guidance on enhancing the diversity of clinical trial populations**](https://www.federalregister.gov/documents/2019/06/07/2019-11978/enhancing-the-diversity-of-clinical-trial-populations-eligibility-criteria-enrollment-practices-and) in 2019. Today's updated guidance aimed at achieving adequate diversity and representation of clinical trial participants is long overdue. As the songwriter, entrepreneur, and activist Sam Cooke said, “It's been a long time coming, but I know a change gonna come.” Now is the time for pharmaceutical companies to show the strategic agility to ensure health equity through diverse and inclusive clinical research. [![Diversifying Clinical Trials White Paper](https://no-cache.hubspot.com/cta/default/19943632/interactive-163343460200.png) ](https://blog.acclinate.com/hs/cta/wi/redirect?encryptedPayload=AVxigLL%2Fw7VbFsk%2FK93H1OFlyLyP9YbiZdum4DTT74OvUQgy7IzRmOWP2Rjb6FRNLHAjBTZHgf9J%2FlRhQhxm%2B25oxgcvaLSsG0TwcwUA0js3%2Fq%2Fi0LCp1BlUyD4JbXQmm6RSZ7IJdFjVOSamK4EH80Nd1HCm34JDJX8Wz%2FbIjkOfK5Gy25hIs4esaJWjOU8ZYiWiSTO2qlaUOsvDRJPc%2BX1SrzlbfYudHRO5wVnwfd6OcuWrFwR212Irn0D8Xw%3D%3D&webInteractiveContentId=163343460200&portalId=19943632) ## Recent Posts [![Clinical Trial Management: The Hidden Risk of Homogeneous Trials in a One-Pivotal-Study World](https://blog.acclinate.com/hubfs/mature-female-patient-at-doctors-appointment-2026-01-08-06-10-47-utc.webp) ](https://blog.acclinate.com/clinical-trial-management-the-hidden-risk-of-homogeneous-trials-in-a-one-pivotal-study-world) [- [Diversity in Clinical Trials](https://blog.acclinate.com/news/tag/diversity-in-clinical-trials) ](https://blog.acclinate.com/clinical-trial-management-the-hidden-risk-of-homogeneous-trials-in-a-one-pivotal-study-world) [ Clinical Trial Management: The Hidden Risk of Homogeneous Trials in a One-Pivotal-Study World ](https://blog.acclinate.com/clinical-trial-management-the-hidden-risk-of-homogeneous-trials-in-a-one-pivotal-study-world) June 25, 2026 3 Min Read Drug development economics are changing. Sponsors are increasingly relying on a single pivotal trial to support approval. Though the goal of this appr... Read More [![Clinical Trial Generalizability: What Regulators Will Scrutinize Next](https://blog.acclinate.com/hubfs/woman-visiting-dermatologist-2026-01-08-22-23-31-utc.webp) ](https://blog.acclinate.com/clinical-trial-generalizability-what-regulators-will-scrutinize-next) [- [Diversity in Clinical Trials](https://blog.acclinate.com/news/tag/diversity-in-clinical-trials) ](https://blog.acclinate.com/clinical-trial-generalizability-what-regulators-will-scrutinize-next) [ Clinical Trial Generalizability: What Regulators Will Scrutinize Next ](https://blog.acclinate.com/clinical-trial-generalizability-what-regulators-will-scrutinize-next) June 25, 2026 3 Min Read For years, generalizability was framed as a methodological concern. Reviewers debated whether results could reasonably extend beyond a trial’s enrolle... Read More [![Site Engagement Index (SEI): Measuring What Actually Builds Trust](https://blog.acclinate.com/hubfs/computer-screen-trading-and-back-with-charts-hom-2026-01-09-09-28-19-utc.webp) ](https://blog.acclinate.com/site-engagement-index-sei-measuring-what-actually-builds-trust) [- [Clinical Research Software](https://blog.acclinate.com/news/tag/clinical-research-software) ](https://blog.acclinate.com/site-engagement-index-sei-measuring-what-actually-builds-trust) [ Site Engagement Index (SEI): Measuring What Actually Builds Trust ](https://blog.acclinate.com/site-engagement-index-sei-measuring-what-actually-builds-trust) June 25, 2026 3 Min Read Clinical research lacks anything but metrics. Enrollment targets, site activation timelines, and digital engagement rates are tracked closely across s... Read More [![](https://blog.acclinate.com/hubfs/Imported_Blog_Media/6567a9f90c0cf111067913e2_Merck%20Pop%20Up2.png) ](https://blog.acclinate.com/acclinate-collaborates-with-merck-to-increase-clinical-trial-diversity) [ Acclinate to support Merck's oncology clinical trials ](https://blog.acclinate.com/acclinate-collaborates-with-merck-to-increase-clinical-trial-diversity) June 24, 2026 1 Min Read Acclinate, an expert in health equity through inclusive research, is collaborating with Merck, known as MSD outside the United States and Canada, to h... Read More [![Why Trial Diversity Is Now a Risk Management Strategy](https://blog.acclinate.com/hubfs/Why-Trial-Diversity-Is-Now-a-Risk-Management-Strategy.jpg) ](https://blog.acclinate.com/why-trial-diversity-is-now-a-risk-management-strategy) [- [Diversity in Clinical Trials](https://blog.acclinate.com/news/tag/diversity-in-clinical-trials) ](https://blog.acclinate.com/why-trial-diversity-is-now-a-risk-management-strategy) [ The New Control Lever: Why Trial Diversity Is Now a Risk Management Strategy ](https://blog.acclinate.com/why-trial-diversity-is-now-a-risk-management-strategy) March 2, 2026 3 Min Read For years, conversations around trial diversity were framed as ethical or reputational concerns. That framing no longer reflects regulatory reality. Read More [![Acclinate’s NOWINCLUDED: Turning Community Insights Into Research Equity](https://blog.acclinate.com/hubfs/AdobeStock_470269560.webp) ](https://blog.acclinate.com/acclinates-nowincluded-turning-community-insights-into-research-equity) [- [Community](https://blog.acclinate.com/news/tag/community) ](https://blog.acclinate.com/acclinates-nowincluded-turning-community-insights-into-research-equity) [ Acclinate’s NOWINCLUDED: Turning Community Insights Into Research Equity ](https://blog.acclinate.com/acclinates-nowincluded-turning-community-insights-into-research-equity) February 16, 2026 3 Min Read Clinical research equity efforts originate with good intentions. But they often hit a roadblock in practice: communities are asked to participate in h... Read More [![How Acclinate’s e-DICT™ Technology Builds Real-Time Community Trust](https://blog.acclinate.com/hubfs/AdobeStock_1631551849.webp) ](https://blog.acclinate.com/how-acclinates-e-dict-technology-builds-real-time-community-trust) [- [Community](https://blog.acclinate.com/news/tag/community) ](https://blog.acclinate.com/how-acclinates-e-dict-technology-builds-real-time-community-trust) [ How Acclinate’s e-DICT™ Technology Builds Real-Time Community Trust ](https://blog.acclinate.com/how-acclinates-e-dict-technology-builds-real-time-community-trust) February 9, 2026 3 Min Read Reaching underrepresented communities in healthcare research has never been simple. Participation decisions are shaped by lived experience, historical... Read More [![Data-Driven Inclusion](https://blog.acclinate.com/hubfs/Acclinate/Blog%20Images/Acclinate-Data-Driven-Inclusion.jpg) ](https://blog.acclinate.com/data-driven-inclusion-predictive-analytics-for-trial-enrollment) [- [Clinical Research Software](https://blog.acclinate.com/news/tag/clinical-research-software) ](https://blog.acclinate.com/data-driven-inclusion-predictive-analytics-for-trial-enrollment) [ Data-Driven Inclusion: Predictive Analytics for Trial Enrollment ](https://blog.acclinate.com/data-driven-inclusion-predictive-analytics-for-trial-enrollment) February 2, 2026 2 Min Read Subpar enrollment remains one of the most common causes of trial delays. But sponsors often miss a key factor: underrepresentation. Lack of diversity ... Read More [![Exploring Diversity in Clinical Research With Acclinate](https://blog.acclinate.com/hubfs/Acclinate/Blog%20Images/Exploring-Diversity-in-Clinical-Research-With-Acclinate.jpg) ](https://blog.acclinate.com/exploring-diversity-in-clinical-research-with-acclinate) [- [Diversity in Clinical Trials](https://blog.acclinate.com/news/tag/diversity-in-clinical-trials) ](https://blog.acclinate.com/exploring-diversity-in-clinical-research-with-acclinate) [ Exploring Diversity in Clinical Research With Acclinate ](https://blog.acclinate.com/exploring-diversity-in-clinical-research-with-acclinate) January 26, 2026 3 Min Read Diversity in clinical research remains a widely discussed goal, yet progress has been uneven. Trials still grapple with subpar representation, limited... Read More [![Clinical Trial Management: The Hidden Risk of Homogeneous Trials in a One-Pivotal-Study World](https://blog.acclinate.com/hubfs/mature-female-patient-at-doctors-appointment-2026-01-08-06-10-47-utc.webp) June 25, 2026 Clinical Trial Management: The Hidden Risk of Homogeneous Trials in a One-Pivotal-Study World Read More ](https://blog.acclinate.com/clinical-trial-management-the-hidden-risk-of-homogeneous-trials-in-a-one-pivotal-study-world) [![Clinical Trial Generalizability: What Regulators Will Scrutinize Next](https://blog.acclinate.com/hubfs/woman-visiting-dermatologist-2026-01-08-22-23-31-utc.webp) June 25, 2026 Clinical Trial Generalizability: What Regulators Will Scrutinize Next Read More ](https://blog.acclinate.com/clinical-trial-generalizability-what-regulators-will-scrutinize-next) [![Site Engagement Index (SEI): Measuring What Actually Builds Trust](https://blog.acclinate.com/hubfs/computer-screen-trading-and-back-with-charts-hom-2026-01-09-09-28-19-utc.webp) June 25, 2026 Site Engagement Index (SEI): Measuring What Actually Builds Trust Read More ](https://blog.acclinate.com/site-engagement-index-sei-measuring-what-actually-builds-trust) ![Woman wearing Acclinate Shirt](https://blog.acclinate.com/hs-fs/hubfs/layer1_image.webp?width=1600&height=1068&name=layer1_image.webp) ![Medical Research Software e-DICT](https://blog.acclinate.com/hs-fs/hubfs/layer2_image.webp?width=885&height=885&name=layer2_image.webp) ![layer2.2_image](https://blog.acclinate.com/hs-fs/hubfs/layer2.2_image.webp?width=1505&height=1197&name=layer2.2_image.webp) ![layer3_image](https://blog.acclinate.com/hs-fs/hubfs/layer3_image.webp?width=1600&height=1067&name=layer3_image.webp) ## Ready to Measure Your True Impact? Partner with Acclinate to turn mission into measurable, data-driven action. [ Get Started ](https://www.acclinate.com/contact-us) [![Acclinate Logo Reversed](https://blog.acclinate.com/hs-fs/hubfs/footer_logo.png?width=1600&height=398&name=footer_logo.png "Acclinate Logo Reversed")](https://www.acclinate.com/) - Products - [NOWINCLUDED](https://www.acclinate.com/products/nowincluded-the-community) - [e-DICT](https://www.acclinate.com/products/e-dict) - Solutions - [Pharmaceutical Companies](https://www.acclinate.com/solutions/for-pharmaceutical-companies) - [CROs](https://www.acclinate.com/solutions/for-cros) - [Community Partners](https://www.acclinate.com/solutions/community-partners) - Resources - [Resources Hub](https://www.acclinate.com/resources) - [Glossary](https://www.acclinate.com/glossary) - [Press Kit](https://www.acclinate.com/press-kit) - [Events](https://www.acclinate.com/events) - [News](https://news.acclinate.com/) - [Blog](https://blog.acclinate.com/) - [FAQs](https://www.acclinate.com/faq) - Company - [About us](https://www.acclinate.com/about) - [Careers](https://www.acclinate.com/careers) - [Contact Us](https://www.acclinate.com/contact-us) - Follow Us - [** Linkedin](https://www.linkedin.com/company/acclinateinc/) - [Privacy Policy](https://www.acclinate.com/privacy) - [Terms of Service](https://www.acclinate.com/terms-of-use-acclinate) ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "author" : { "@type" : "Person", "name" : "Acclinate", "url" : "https://blog.acclinate.com/author/acclinate" }, "dateModified" : "2026-01-22T17:16:13.607Z", "datePublished" : "2022-04-18T21:17:00.000Z", "headline" : "New FDA Guidance on Clinical Trial Diversity", "image" : [ "https://blog.acclinate.com/hubfs/11.png" ], "mainEntityOfPage" : { "@id" : "https://blog.acclinate.com/a-change-gone-come-assessing-pharmas-response-to-new-fda-guidance-on-clinical-trial-diversity", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://blog.acclinate.com/hubfs/Acclinate-logo.png" }, "name" : "Acclinate" } } ```